paid-only post Nov 11, 2025 activistcompany BML Capital condemns Adverum Biotechnologies, Inc (ADVM) merger with Eli Lilly as flawed and value-destructive This post is for paying subscribers only Subscribe to continue reading Subscribe now Already have an account? Sign in
Voss Capital Urges Xponential Fitness (XPOF) to Explore Sale, Citing Undervaluation of Club Pilates Mar 5, 2026
Oramed Pharmaceuticals Flags Management Concerns, Plans Continued Engagement on Strategy and Governance at Nano Dimension (NNDM) Mar 4, 2026
Galloway Capital Flags Undervaluation and Pushes for Shareholder Value Actions at GSI Technology (GSIT) Mar 3, 2026